<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-9721</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Imunoalergologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Imunoalergologia]]></abbrev-journal-title>
<issn>0871-9721</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Alergologia e Imunologia Clínica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-97212025000100039</article-id>
<article-id pub-id-type="doi">10.32932/rpia.2025.03.155</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Avaliação da qualidade de vida em doentes com imunodeficiência comum variável sob tratamento com imunoglobulina endovenosa]]></article-title>
<article-title xml:lang="en"><![CDATA[Quality of life evaluation in patients with common variable immunodeficiency treated with intravenous immunoglobulin]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[Liliana Pereira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Areia]]></surname>
<given-names><![CDATA[Margarida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cadinha]]></surname>
<given-names><![CDATA[Susana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gomes]]></surname>
<given-names><![CDATA[Joana Queirós]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guilherme]]></surname>
<given-names><![CDATA[Arminda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Unidade Local de Saúde Gaia-Espinho Serviço de Imunoalergologia ]]></institution>
<addr-line><![CDATA[Vila Nova de Gaia ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<volume>33</volume>
<numero>1</numero>
<fpage>39</fpage>
<lpage>48</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212025000100039&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212025000100039&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-97212025000100039&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  A imunodeficiência comum variável (IDCV) é a imunodeficiência primária sintomática mais frequente. Caracteriza-se por apresentar uma enorme heterogeneidade de manifestações clínicas, imunológicas e genéticas, sendo por isso considerada um &#8220;diagnóstico em guarda-chuva&#8221;. O maior reconhecimento e os progressos no tratamento da IDCV permitiram aumentar a sobrevida dos doentes. No entanto, a reposição de imunoglobulina humana permanece a base do tratamento. A perspetiva do doente sobre a qualidade de vida (QV) relacionada com a saúde, como um fator que influencia o bem-estar e a funcionalidade física e emocional, é cada vez mais explorada nos cuidados de saúde. O objetivo deste estudo foi avaliar a QV dos doentes com IDCV sob terapêutica de substituição com imunoglobulina endovenosa, aplicando o questionário de QV MOS SF-36.  Métodos:  Foram incluídos 23 doentes com IDCV seguidos na consulta de Imunoalergologia-Imunodeficiências Primárias da Unidade Local de Saúde Gaia-Espinho, que responderam ao questionário de QV (MOS SF-36). Compararam-se os valores de QV dos doentes com valores de referência previamente publicados, referentes a uma amostra representativa da população portuguesa (n=2459). Os valores das diferentes dimensões de QV foram comparados segundo o sexo, idade de início dos sintomas/diagnóstico/atual, presença de infeções recorrentes e complicações não infeciosas.  Resultados:  Os doentes com IDCV apresentaram uma diminuição estatisticamente significativa da componente física e mental. Na componente física, o desempenho e a dor física foram os mais afetados. Nos parâmetros que avaliam a componente mental, a saúde mental, função social e vitalidade, também apresentaram uma diminuição significativa. As diferenças encontradas foram independentes da idade de diagnóstico, tempo até ao diagnóstico, sexo e complicações não infeciosas.  Conclusão:  Os doentes em seguimento por IDCV apresentam diminuição significativa da componente física e mental da qualidade de vida. Salientamos a relevância de uma avaliação multidisciplinar adequada às necessidades de cada doente com o objetivo de intervir nos parâmetros afetados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Common Variable Immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in adulthood. It is characterized by heterogeneous clinical, immunological, and genetic manifestations and is therefore considered an &#8220;umbrella diagnosis&#8221;. Greater recognition and progress in the treatment of CVID has led to increased patient survival. However, human immunoglobulin replacement remains the first-line treatment. Acknowledgment of the patient&#8217;s perspective regarding health-related quality of life (QoL) as a factor influencing well-being in both physical and mental domains is emerging in healthcare. This study aimed to evaluate the QoL of patients with CVID undergoing intravenous immunoglobulin replacement therapy, applying the MOS SF-36 QoL questionnaire.  Methods:  We included 23 patients with CVID followed in the Allergy and Clinical Immunology department at the Unidade Local de Saúde Gaia-Espinho. The patients&#8217; QoL questionnaire scores were compared with previously published reference values from a sample of the Portuguese population (n=2459). Scores of diferente QoL dimensions were analyzed regarding age, sex, age at onset of symptoms/diagnosis/current, recurrent infections, and comorbidities.  Results:  CVID patients showed a statistically significant decrease in the physical and mental domains. In the physical domain, patients expressed significantly lower scores in functioning and physical pain. The subgroup scores for mental health, social function, and vitality in the mental component also showed a significant decrease. There was no significant correlation between age at diagnosis, time until diagnosis, sex, and non-infectious comorbidities.  Conclusion:  CVID patients show a significant reduction in the physical and mental parameters of QoL. We emphasize the relevance of a multidisciplinary approach to assess their individual needs regarding the affected parameters.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Imunodeficiência comum variável]]></kwd>
<kwd lng="pt"><![CDATA[qualidade de vida]]></kwd>
<kwd lng="pt"><![CDATA[questionário MOS SF-36]]></kwd>
<kwd lng="pt"><![CDATA[saúde física]]></kwd>
<kwd lng="pt"><![CDATA[saúde mental]]></kwd>
<kwd lng="en"><![CDATA[Common variable immunodeficiency]]></kwd>
<kwd lng="en"><![CDATA[quality of life]]></kwd>
<kwd lng="en"><![CDATA[MOS SF-36 questionnaire]]></kwd>
<kwd lng="en"><![CDATA[mental health]]></kwd>
<kwd lng="en"><![CDATA[physical health]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Notarangelo]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Geha]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Casanova]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Conley]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary immunodeficiencies]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2009</year>
<volume>124</volume>
<page-range>1161-78</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bjorkander]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Webster]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Grimbacher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common variable immunodeficiency disorders: division into distinct clinical phenotypes]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>112</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>277-86</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seidel]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Kindle]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gathmann]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Quinti]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Buckland]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Montfrans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2019</year>
<volume>7</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1763-70</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonilla]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Barlan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Costa Carvalho]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham-Rundles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Morena]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International Consensus Document (ICON): Common Variable Immunodeficiency Disorders]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2016</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-59</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonagura]]></surname>
<given-names><![CDATA[VR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using intravenous immunoglobulin to treat patients with primary immune deficiency disease]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2013</year>
<volume>33</volume>
<page-range>S90-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lucas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lortan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Granados]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Misbah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2010</year>
<volume>125</volume>
<page-range>1354-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ameratunga]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Woon]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspective: evolving concepts in the diagnosis and understanding of common variable immunodeficiency disorders(CVID)]]></article-title>
<source><![CDATA[Clinic Rev Allerg Immunol]]></source>
<year>2020</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>109-21</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salzer]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Warnatz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Peter]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common variable immunodeficiency - an update]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2012</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>223</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[von der Lippe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Diesen]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Feragen]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Living with a rare disorder: A systematic review of the qualitative literature]]></article-title>
<source><![CDATA[Mol Genet Genomic Med]]></source>
<year>2017</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>758-73</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bogart]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Irvin]]></surname>
<given-names><![CDATA[VL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life among adults with diverse rare disorders]]></article-title>
<source><![CDATA[Orphanet J Rare Dis]]></source>
<year>2017</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>177</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quinti]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Di Pietro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martini]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pesce]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lombardi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Baumghartner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health related quality of life in common variable immunodeficiency]]></article-title>
<source><![CDATA[Yonsei Med J]]></source>
<year>2012</year>
<volume>53</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>603-10</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenderking]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Anatchkova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pokrzywinski]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Skalicky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Gelhorn]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measuring health-related quality of life in patients with rare disease]]></article-title>
<source><![CDATA[J Patient Rep Outcomes]]></source>
<year>2021</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>61</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Midttun]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Feragen]]></surname>
<given-names><![CDATA[KJB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measuring quality of life of primary antibody deficiency patients using a disease-specific health-related quality of life questionnaire for common variable immunodeficiency (CVID_QoL)]]></article-title>
<source><![CDATA[J Patient Rep Outcomes]]></source>
<year>2019</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Da Silva]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Avaliação da qualidade de vida em doentes com angioedema hereditário]]></article-title>
<source><![CDATA[Rev Port Imunoalergologia]]></source>
<year>2011</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>143-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Cowan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Condino-Neto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Prusty]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life in primary immunodeficiencies: Impact of delayed diagnosis and treatment burden]]></article-title>
<source><![CDATA[Clin Immunol]]></source>
<year>2022</year>
<volume>236</volume>
<page-range>108931</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criac&#807;a&#771;o da versa&#771;o portuguesa do MOS SF-36, Parte I-Adaptac&#807;a&#771;o cultural e linguistica]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2000</year>
<volume>13</volume>
<page-range>55-66</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Criac&#807;a&#771;o da versa&#771;o portuguesa do MOS SF-36, Parte II-Testes de validac&#807;a&#771;o]]></article-title>
<source><![CDATA[Acta Med Port]]></source>
<year>2000</year>
<volume>13</volume>
<page-range>119-27</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Percepc&#807;a&#771;o de estado de sau&#769;de e de qualidade de vida da populac&#807;a&#771;o activa: contributo para a definic&#807;a&#771;o de normas portuguesas]]></article-title>
<source><![CDATA[Rev Port Sau Pub]]></source>
<year>2003</year>
<volume>21</volume>
<page-range>15-30</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pulvirenti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cinetto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Milito]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bonanni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pesce]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Leodori]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life in common variable immunodeficiency italian patients switched to remote assistance during the COVID-19 pandemic]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2020</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1894-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Gereige]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Maglione]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[State-of-the-art diagnostic evaluation of common variable immunodeficiency]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>2021</year>
<volume>127</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-27</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rider]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Kutac]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hajjar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Scalchunes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Seeborg]]></surname>
<given-names><![CDATA[FO]]></given-names>
</name>
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life in adult patients with common variable immunodeficiency disorders and impact of treatment]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2017</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>461-75</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[M. Lucas]]></given-names>
</name>
<name>
<surname><![CDATA[M. Lee]]></surname>
<given-names><![CDATA[J. Bjorkander]]></given-names>
</name>
<name>
<surname><![CDATA[D. Webster]]></surname>
<given-names><![CDATA[B. Grimbacher]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Common variable immunodeficiency disorders: division into distinct clinical phenotypes]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>112</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>277-86</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[B. Gathmann]]></surname>
<given-names><![CDATA[N. Mahlaoui]]></given-names>
</name>
<name>
<surname><![CDATA[L. Gérard]]></surname>
<given-names><![CDATA[E. Oksenhendler]]></given-names>
</name>
<name>
<surname><![CDATA[K. Warnatz]]></surname>
<given-names><![CDATA[I. Schulze]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical picture and treatment of 2212 patients with common variable immunodeficiency]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>2014</year>
<volume>134</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>116-26</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ho]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham-Rundles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-infectious complications of common variable immunodeficiency: Updated clinical spectrum, sequelae, and insights to pathogenesis]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2020</year>
<volume>7</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>149</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Routes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Costa-Carvalho]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Grimbacher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Paris]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ochs]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Filipovich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment]]></article-title>
<source><![CDATA[J Clin Immunol]]></source>
<year>2016</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>450-61</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quinti]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pulvirenti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Giannantoni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hajjar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Canter]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Milito]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and initial validation of a questionnaire to measure health-related quality of life of adults with common variable immune deficiency: The CVID_QoL questionnaire]]></article-title>
<source><![CDATA[J Allergy Clin Immunol Pract]]></source>
<year>2016</year>
<volume>4</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1169-79</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
